Dina Chaya, PhD
Partner, NeoMed Management
Dina joined NeoMed in 2009. She manages NeoMed’s funds and assists with and advises on new investments for Omega. Dina has been investing in the private equity and venture capital healthcare industry since 2001. Previously at 3i in London and Index Ventures in Geneva, her recent investments including Attenua, Imago BioSciences, Oxular, TopiVert, Wilson Therapeutics, EUSA Pharma, Endosense and Novexel.
Dina is a member of the Venture Capital Platform Council of Invest Europe. She is a CFA charterholder and holds a Ph.D. degree in Molecular and Cellular Biology from Paris VI University, France and carried out postdoctoral research at Brown University, Providence, US, and at the Fox Chase Cancer Centre, Philadelphia, US.